Current filters:

Start a new search
Add filters:

Use filters to refine the search results.

Results 81-90 of 112
Item hits:
Issue DateTitleAuthor(s)
15-Aug-2017Differential Expression of VEGF-Axxx Isoforms Is Critical for Development of Pulmonary Fibrosis.Barratt, SL; Blythe, T; Jarrett, C; Ourradi, K; Shelley-Fraser, G, et al
15-Jun-2017Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trialSaunders, P; Tsipouri, V; Keir, GJ; Ashby, D; Flather, MD, et al
14-Nov-2017An epithelial biomarker signature for idiopathic pulmonary fibrosis: an analysis from the multicentre PROFILE cohort study.Maher, TM; Oballa, E; Simpson, JK; Porte, J; Habgood, A, et al
14-Nov-2017Phenotypic characteristics associated with slow gait speed in idiopathic pulmonary fibrosisNolan, CM; Maddocks, M; Maher, TM; Canavan, JL; Jones, SE, et al
1-Jun-2013Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosisFingerlin, TE; Murphy, E; Zhang, W; Peljto, AL; Brown, KK, et al
19-Jun-2013Reducing lung function decline in patients with idiopathic pulmonary fibrosis: potential of nintedanibWoodcock, HV; Molyneaux, PL; Maher, TM
25-Sep-2012Current and novel drug therapies for idiopathic pulmonary fibrosisAdamali, HI; Maher, TM
3-Mar-2014The treatment of idiopathic pulmonary fibrosisWoodcock, HV; Maher, TM
4-Sep-2018Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: design of a double-blind, randomised, placebo-controlled phase II trial.Maher, TM; Corte, TJ; Fischer, A; Kreuter, M; Lederer, DJ, et al
8-Jul-2019Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseasesWollin, L; Distler, JHW; Redente, EF; Riches, DWH; Stowasser, S, et al